EP3387151A1 — Compositions and methods for the diagnosis and treatment of bone fractures and disorders
Assigned to Universitaet fuer Bodenkultur Wien BOKU · Expires 2018-10-17 · 8y expired
What this patent protects
The present invention relates to the therapy, prophylaxis and diagnosis of disorders that are associated with aberrant bone mineral density, in particular osteoporosis; wherein the level of selected microRNAs in samples of patients are detected and wherein an increase or decrease…
USPTO Abstract
The present invention relates to the therapy, prophylaxis and diagnosis of disorders that are associated with aberrant bone mineral density, in particular osteoporosis; wherein the level of selected microRNAs in samples of patients are detected and wherein an increase or decrease of said level compared to the level of healthy indivduals is indicative of the disorder.
Drugs covered by this patent
- Skyclarys (OMAVELOXOLONE) · Biogen Us
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.